1
points
1
8.8
years
10.8
years
0
points
0
points
0
points
1
points
1
8.8
years
10.8
years
0
points
0
points
0
points
The IPSS-R (Revised International Prognostic Scoring System) is the current standard for prognostic assessment in myelodysplastic syndromes (MDS). Published by Greenberg and colleagues in 2012 in Blood, the IPSS-R refined the original IPSS by providing more granular scoring of cytogenetic risk groups, bone marrow blast percentage, and cytopenias, resulting in significantly improved prognostic discrimination.
Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a variable risk of transformation to acute myeloid leukemia (AML). MDS affects approximately 3-5 per 100,000 people annually, with incidence increasing dramatically with age. Median age at diagnosis is approximately 70 years.
The IPSS-R evaluates five prognostic variables: cytogenetic risk category (5 groups from very good to very poor), bone marrow blast percentage (4 levels), hemoglobin level, platelet count, and absolute neutrophil count. Each variable is scored on a continuous scale and summed to produce a total score that classifies patients into five risk categories.
The five IPSS-R risk categories are: very low (score <=1.5, median survival 8.8 years), low (>1.5-3.0, median 5.3 years), intermediate (>3.0-4.5, median 3.0 years), high (>4.5-6.0, median 1.6 years), and very high (>6.0, median 0.8 years). This five-tier system provides substantially better discrimination than the original four-tier IPSS.
The IPSS-R directly informs treatment decisions in MDS. Lower-risk patients (very low and low) are typically managed with observation, erythropoiesis-stimulating agents, lenalidomide (for del(5q)), or luspatercept. Higher-risk patients (high and very high) may be candidates for hypomethylating agents (azacitidine, decitabine), intensive chemotherapy, or allogeneic hematopoietic stem cell transplantation (allo-HSCT), the only curative treatment for MDS.
The intermediate-risk category represents a decision point where treatment approach depends on additional factors including age, comorbidities, transfusion requirements, and patient preferences. Some intermediate-risk patients may be managed conservatively while others may benefit from more aggressive approaches including transplantation.
The IPSS-R score sums five components:
Risk Category: 1=Very Low (<=1.5), 2=Low (>1.5-3), 3=Intermediate (>3-4.5), 4=High (>4.5-6), 5=Very High (>6).
Very Low risk (Category 1): Median survival ~8.8 years. Observation or supportive care. Low risk (Category 2): ~5.3 years. ESAs, lenalidomide if del(5q). Intermediate (Category 3): ~3.0 years. Treatment decision depends on additional factors. High (Category 4): ~1.6 years. Hypomethylating agents, consider transplant. Very High (Category 5): ~0.8 years. Urgent treatment needed, transplant evaluation if eligible.
Inputs
Results
Good cytogenetics, low blasts, mild anemia. IPSS-R 2.0, low risk. Median survival 5.3 years.
Inputs
Results
Very poor cytogenetics, high blasts, severe cytopenias. IPSS-R 10.0, very high risk. Urgent treatment needed.
The IPSS-R (Revised International Prognostic Scoring System) is the standard prognostic tool for myelodysplastic syndromes. It scores cytogenetics, blast percentage, hemoglobin, platelets, and neutrophil count to classify patients into five risk categories.
IPSS-R has 5 cytogenetic risk groups (vs 3), more granular blast percentage scoring, includes hemoglobin and ANC as separate variables, and creates 5 risk categories (vs 4). It provides significantly better prognostic discrimination.
Cytogenetic risk category is the strongest single prognostic factor, accounting for the widest score range (0-4 points). Bone marrow blast percentage is the second most important factor.
Allogeneic stem cell transplant, the only curative therapy, is typically considered for higher-risk patients (high and very high IPSS-R) who are medically fit. Some intermediate-risk patients may also benefit from transplant.
Azacitidine and decitabine are drugs that reverse abnormal DNA methylation in MDS cells. They are the primary treatment for higher-risk MDS and can improve blood counts, reduce transfusion dependence, and delay AML transformation.
Yes, MDS is a progressive disease and IPSS-R should be reassessed when clinical status changes. Worsening cytopenias, rising blast percentage, or new cytogenetic abnormalities may indicate disease progression and higher IPSS-R category.
Very low risk: ~2% at 5 years. Low: ~5%. Intermediate: ~15%. High: ~40%. Very high: ~65%. Higher IPSS-R categories have substantially greater risk of evolving to acute myeloid leukemia.
Very good cytogenetics include isolated del(11q) and isolated loss of Y chromosome. These carry the best prognosis and score 0 points on the IPSS-R.
Age is not directly included in IPSS-R scoring, but it heavily influences treatment decisions. Younger patients with higher-risk IPSS-R are more likely to be transplant candidates.
The IPSS-R was developed before routine molecular testing. Newer models like IPSS-M incorporate mutational data (TP53, SF3B1, ASXL1, etc.) and may eventually supplement or replace IPSS-R for more precise prognostication.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
NCCN-IPI (Lymphoma)
Oncology Risk & Prognosis Calculators
IPI24 (Lymphoma)
Oncology Risk & Prognosis Calculators
R-IPI (Revised IPI for Lymphoma)
Oncology Risk & Prognosis Calculators
WPSS (WHO Prognostic Scoring System)
Oncology Risk & Prognosis Calculators
ISS (International Staging System for Myeloma)
Oncology Risk & Prognosis Calculators
R-ISS (Revised ISS for Myeloma)
Oncology Risk & Prognosis Calculators
